Targeted Molecular Treatments in Non-Small Cell Lung Cancer: A Clinical Guide for Oncologists

  • Bui K
  • Cooper W
  • Kao S
  • et al.
N/ACitations
Citations of this article
16Readers
Mendeley users who have this article in their library.

Abstract

Targeted molecular treatments have changed the way non-small cell lung cancer (NSCLC) is managed. Epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), v-raf murine sarcoma viral oncogene homolog B1 (BRAF), and c-ros oncogene 1 (ROS1) mutations are now used to guide specific anti-cancer therapies to improve patient outcomes. New targeted molecular treatments are constantly being developed and evaluated as a means to improve efficacy, overcome resistance, or minimise toxicity. This review article summarises the current evidence for the efficacy, resistance mechanisms, and safety of targeted molecular treatments against specific mutations in NSCLC.

Cite

CITATION STYLE

APA

Bui, K. T., Cooper, W. A., Kao, S., & Boyer, M. (2018). Targeted Molecular Treatments in Non-Small Cell Lung Cancer: A Clinical Guide for Oncologists. Journal of Clinical Medicine, 7(8), 192. https://doi.org/10.3390/jcm7080192

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free